Promises and pitfalls of immune-based strategies for Huntington's disease  

作　　者：Gabriela Delevati Colpo Erin Furr Stimming Natalia Pessoa Rocha Antonio Lucio Teixeira 

机构地区：[1]Neuropsychiatry Program, Department of Psychiatry and Behavioral Sciences, Mc Govern Medical School, The University of Texas Health Science Center at Houston [2]Department of Neurology, McGovern Medical School, The University of Texas Health Science Center at Houston

出　　处：《Neural Regeneration Research》2017年第9期1422-1425,共4页中国神经再生研究（英文版）

摘　　要：Huntington＇s disease （HD） is an autosomal-dominant neurodegenerative disease characterized by the selec- tive loss of neurons in the striatum and cortex, leading to progressive motor dysfunction, cognitive decline and behavioral symptoms. HD is caused by a trinucleotide （CAG） repeat expansion in the gene encoding for huntingtin. Several studies have suggested that inflammation is an important feature of HD and it is already observed in the early stages of the disease. Recently, new molecules presenting anti-inflammatory and/or immunomodulatory have been investigated for HD. The objective of this review is to discuss the data obtained so far on the immune-based therapeutic strategies for HD.Huntington＇s disease （HD） is an autosomal-dominant neurodegenerative disease characterized by the selec- tive loss of neurons in the striatum and cortex, leading to progressive motor dysfunction, cognitive decline and behavioral symptoms. HD is caused by a trinucleotide （CAG） repeat expansion in the gene encoding for huntingtin. Several studies have suggested that inflammation is an important feature of HD and it is already observed in the early stages of the disease. Recently, new molecules presenting anti-inflammatory and/or immunomodulatory have been investigated for HD. The objective of this review is to discuss the data obtained so far on the immune-based therapeutic strategies for HD.

关 键 词：Huntington＇s disease treatment disease modifying therapy INFLAMMATION 

分 类 号：R742.2[医药卫生—神经病学与精神病学]